Aquestive Therapeutics, Inc. - Common Stock, Par Value $0.001 Per Share (AQST)

CUSIP: 03843E104

Q2 2022 13F Holders as of 30 Jun 2022

Holder snapshot 7 signals
Share change
+1,206,479
Put/Call ratio
0%
SEC-reported price per share
$0.64
Number of holders
37
Value change
-$1,110,269
Number of buys
15
Open additional details 1 more signal available
Number of sells
25
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
125,140,813

Security key

03843E104

Report period

Q2 2022

Institutions

37

Top holders

10

Ownership snapshot

Top reported holders of AQST - Aquestive Therapeutics, Inc. - Common Stock, Par Value $0.001 Per Share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Bratton Capital Managemen...
Disclosed value leader
Bratton Capital Managemen...
Comparable rows
0/15
Latest evidence
31 Mar 2022
13F Highest disclosed value: $25,607,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Bratton Capital Management, L.P. has the largest disclosed position value at $25.61M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bratton Capital Management, L.P.'s linked filing trail.
Disclosed position value Top 5
Bratton Capital Management, L.P. $25.61M
VANGUARD GROUP INC $3.35M
Vahanian & Associates Financial P... $1.36M
Bracebridge Capital, LLC $1.12M
Graypoint LLC $1.08M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Bratton Capital Management, L.P.
13F
Company
13F
—
denominator unverified
$25,607,000
9,810,958 shares
— 31 Mar 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$3,347,000
1,282,506 shares
— 31 Mar 2022
Vahanian & Associates Financial Planning Inc.
13F
Company
13F
—
denominator unverified
$1,358,000
520,158 shares
— 31 Mar 2022
Bracebridge Capital, LLC
13F
Company
13F
—
denominator unverified
$1,119,000
428,571 shares
— 31 Mar 2022
Graypoint LLC
13F
Company
13F
—
denominator unverified
$1,080,000
413,817 shares
— 31 Mar 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$983,000
376,517 shares
— 31 Mar 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
37
Shares
16,697,754
Rows available
37
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders
49
Q2 2022 holders
37
Holder diff
-12
Investor Q1 2022 Shares Q2 2022 Shares Share Diff Share Chg % Q1 2022 value Q2 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .